maliqun61 schreef op 4 december 2018 13:27:
[...]
Ben ook wel benieuwd naar de kosten, die overigens voor de baat uitgaan.
Announced five studies ongoing or starting to expand the pipeline strongly:
- An ongoing
investigator-sponsored study of RUCONEST® in Basel, Switzerland in a double-blind, placebo-controlled trial in contrast-induced nephropathy, with top-line data expected in Q3 2018
- A new Phase I/II study of rhC1INH in pre-eclampsia to be filed by Pharming shortly to start in Q4 2018
- An ongoing
investigator-sponsored study of RUCONEST® head-to-head against a
competitor in a trial testing therapy failure rates in treating acute attacks of hereditary angioedema (“HAE”), with top-line data expected in Q4 2018
- Initiation of an i
nvestigator-sponsored study of RUCONEST® to treat delayed graft function, a form of ischemic reperfusion injury, at the University of Wisconsin
- A new
in-house clinical trial of Pharming’s proprietary recombinant human alphaglucosidase in Pompe disease to be filed early 2019
Bron: halfjaar bericht juli 2018